-
GRIT Biotechnology’s GT201 TIL Therapy Approved for Clinical Studies by China’s CDE
•
The Center for Drug Evaluation (CDE) website has indicated that GRIT Biotechnology, a China-based cell therapy specialist, has received approval for its in-house developed gene engineered tumor-infiltrating lymphocyte (TIL) therapy, GT201, for clinical studies in patients with recurrent or metastatic solid tumors. Optimal Structural Design and Custom Retroviral System for…
-
Novartis Terminates TIGIT-Targeted Antibody Deal with BeiGene, Retains Rights to Ociperlimab
•
Swiss pharmaceutical giant Novartis AG (NYSE: NVS) has decided to terminate an option and license deal with China-based BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235), which was focused on the development of BeiGene’s TIGIT-targeted antibody drug, ociperlimab. The initial deal, signed in December 2021, included a USD 300 million upfront…
-
Biocytogen Pharmaceuticals Awarded CNIPA Patent for RenMab Human Antibody Mice Platform
•
Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315), a China-based biopharmaceutical company, has announced receiving a patent award from the China National Intellectual Property Administration (CNIPA) for its in-house developed human antibody mice RenMab platform. The patent, titled “Genetically modified non-human animals with humanized immunoglobulin loci”, is valid through February 18,…
-
Guangdong’s OptoMedic Secures Over $27.8 Million in Pre-IPO Financing for Endoscopy Innovations
•
OptoMedic Technologies, Inc., a leading endoscopy specialist based in Guangdong, has reportedly raised upwards of RMB 200 million (USD 27.8 million) in a pre-IPO financing round. The round was led by CCB Private Equity Investment and Huajin Capital, with participation from Guoxin Capital and Befor Capital. The funds will be…
-
Jiangsu Hengrui Pharmaceuticals’ Irinotecan and Bupivacaine Liposome Injections Get Clinical Trial Green Light in China
•
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a China-based pharmaceutical company, has announced receiving separate clinical trial approvals in China for its irinotecan liposome injection and bupivacaine liposome injection. These approvals mark a significant step forward in the development of these targeted therapies. Irinotecan Liposome Injection for Advanced Colorectal Cancer…
-
Shanghai Junshi Biosciences’ Tuoyi Files for 9th Indication in China for RCC Treatment
•
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has announced that the National Medical Products Administration (NMPA) has accepted for review an additional indication approval filing for its Tuoyi (toripalimab), a programmed death-1 (PD-1) inhibitor, in combination with axitinib for first-line unresectable or metastatic renal cell carcinoma (RCC). This…
-
Jiangsu Hengrui Pharmaceuticals Receives Clinical Trial Approvals for Irinotecan and Bupivacaine Liposome Injections
•
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a China-based pharmaceutical company, has announced receiving separate clinical trial approvals in China for its irinotecan liposome injection and bupivacaine liposome injection. These approvals mark significant steps in advancing the company’s pipeline in oncology and pain management. Irinotecan Liposome Injection for Advanced Colorectal…
-
Shanghai Junshi Biosciences’ Tuoyi Files for 9th Indication in China for RCC Treatment
•
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has announced that the National Medical Products Administration (NMPA) has accepted for review an additional indication approval filing for its Tuoyi (toripalimab), a programmed death-1 (PD-1) inhibitor, in combination with axitinib for first-line unresectable or metastatic renal cell carcinoma (RCC). This…
